Implementing Risk-based Monitoring in Oncology Trials Sharing case studies and insights on the impact to study quality and patient safety



***Live: Thursday November 12, 2020 at 11am EST***Oncology trials of various types and phases present unique challenges for effectively conducting trials, and firms are implementing risk-based monitoring (RBM) practices to improve quality and patient safety.***On demand available after final airing until Nov. 12, 2021***

Top 5 Strategies for Conducting an Effective Data Monitoring Committee (DMC)

Register Free:

Event Overview: Clinical research & development is at a crossroads, requiring new approaches to deliver drugs to market faster – with less cost – while mitigating risk, and without compromising safety or quality. The market is moving towards risk-based monitoring (RBM) to monitor clinical trials as it provides new levels of efficiency and quality while providing predictability of speed and operational outcomes.

Key Learning Objectives:

  • The industry continues to change, and risk-based monitoring (RBM) is helping pharmaceutical firms improve the efficiency, quality and safety of their oncology trials to bring new therapies to patients faster
  • RBM is using advanced technologies, including AI, ML, and predictive analytics to provide new levels of insights to mitigate risks while improving quality and patient safety
  • Oncology trials are an industry leader in the adoption of RBM practices for their clinical trials – understand why with case studies and lessons learned from this webinar

Speakers: Zabir Macci, Centralized Monitoring Manager, Clinical Operations Process Design,Analytics, IQVIA

Susana Nolley, MPH,mDirector, Clinical Project Management, Oncology Project Leadership, IQVIA

Time and Date: Thursday November 12, 2020 at 11am EST

On demand until Nov. 12 2021.

Sponsor: IQVIA

Register Free:

Related Content
© 2024 MJH Life Sciences

All rights reserved.